A phase II study of fazarabine in patients with advanced ovarian cancer. A Gynecologic Oncology Group study.
BACKGROUND
A total of 22 patients with recurrent ovarian cancer previously treated with cisplatin-containing chemotherapy were treated with Fazarabine.


METHODS
The drug was administered at an initial dose of 30 mg/m2/day for 5 consecutive days. Cycles were repeated every 28 days. There were 19 evaluable patients.


RESULTS
No complete or partial responders were observed in this study; 48% of patients were deemed to have stable disease. The major toxicity was hematologic, with four patients exhibiting grade 4 neutropenia.


CONCLUSIONS
Fazarabine shows no useful activity as a single agent when given at this dose and schedule in the management of previously treated patients with cancer of the ovary.
Manetta
A
A
Division of Gynecologic Oncology, University of California, Irvine Medical Center 92668.
Blessing
J A
JA
Look
K Y
KY
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C022121:fazarabine; D001374:Azacitidine